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Abstract
Background: Malignant small bowel tumors are very rare and leiomyosarcoma accounts for less
than 15% of the cases. Management of these tumors is challenging in view of nonspecific symptoms,
unusual presentation and high incidence of metastasis. In this case report, an unusual presentation
of jejunal sarcoma and management of liver metastasis with radiofrequency ablation (RFA) is
discussed.
Case presentation: A 45-year-old male presented with anemia and features of small bowel
obstruction. Operative findings revealed a mass lesion in jejunum with intussusception of proximal
loop. Resection of bowel mass was performed. Histopathological findings were suggestive of
leiomyosarcoma. After 3-years of follow-up, the patient developed recurrence in infracolic
omentum and a liver metastasis. The omental mass was resected and liver lesion was managed with
radiofrequency ablation.
Conclusion: Jejunal leiomyosarcoma is a rare variety of malignant small bowel tumor and a clinical
presentation with intussusception is unusual. We suggest that an aggressive management approach
using a combination of surgery and a newer technique like RFA can be attempted in patients with
limited metastatic spread to liver to prolong the long-term survival in a subset of patients.
Background
Malignant tumors of the small bowel are rare and
accounts for the <2 % of total gastrointestinal (GI) malig-
nancy [1,2]. The age-adjusted incidence of small bowel
malignancy is 1 per 100,000 with prevalence of 0.6% [3].
Management of these tumors is challenging because of
their rarity, relative inaccessibility for diagnosis and
diverse histologic types and nonspecific symptoms [4].
Because of the heterogenous and aggressive nature many
of them present with recurrence and visceral metastasis.
Radiofrequency ablation has been successfully tried as a
minimally invasive but effective local treatment of liver
metastasis from a variety of primary sites including small
bowel tumors [5]. In this case report, we present an
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unusual case of small bowel sarcoma, and discuss the clin-
ical presentation and management using combination of
surgery and radiofrequency ablation (RFA).
Case presentation
A 45-year-old male was referred to our center with the
diagnosis of suspected non-Hodgkin's lymphoma (NHL)
of the bowel in December 1999. He had generalized
weakness for 2-years along with recurrent vomiting, occa-
sional constipation and melaena for last 2 months. The
diagnosis was considered after an ultrasound (USG)
guided fine needle aspiration cytology (FNAC) from the
intra-abdominal mass done elsewhere and showed fea-
tures suspicious of NHL.
At presentation, patient's general condition was poor and
he was dehydrated and pale. There was no peripheral lym-
phaedenopathy. Abdominal examination revealed an ill-
defined, mobile, nontendor lump in left paraumblical
region extending up to left lumber region. There was no
hepato-splenomegaly. Examination of chest and cardio-
vascular system was normal. After initial resuscitation
with crystalloids and blood transfusion, patient was fur-
ther investigated.
At presentation his hemoglobin was low (6.4 gm%) but
rest of the routine haematological investigations were
within normal limit. The chest X-ray was normal. Abdom-
inal ultrasound (USG) showed a left upper abdominal
mass lesion suggestive of bowel mass. The upper GI
endoscopy was normal. The barium meal follow through
examination was suggestive of intussusception of proxi-
mal jejunum and a suspected mass lesion at the leading
edge of intussusceptum. An USG guided core needle
biopsy of mass was performed because of earlier suspicion
of NHL, which showed smooth muscle bundles with areas
of necrosis. Based on the above findings and biopsy
report, patient was taken up for exploratory laparotomy 3
weeks after initial presentation.
Operative findings revealed an intussuscepted proximal
jejunum loop 12 cm distal to duodeno-jejunal flexure and
a vascular polypoidal growth measuring 6.5 × 5 × 3.5 cms
on serosal surface of jejunum. Liver and spleen were nor-
mal. There was no evidence of mesenteric or retroperito-
neal lymphaedenopathy, ascites or peritoneal disease. The
resection of involved segment of jejunum with 5 cm mar-
gins and an end-to-end anastomosis was performed. The
postoperative course was uneventful.
Pathological examination of the specimen revealed two
mass lesions measuring 4.5 cm & 3 cm in continuity (total
7.5 cm in maximum diameter) located on mucosal and
serosal surface of jejunum respectively. Microscopically it
showed spindle cell tumor with a mitotic rate of 5/10 high
power fields (HPF). The tumor was negative for desmin,
S-100, CD 34 and c-kit (CD117) but focally positive for
actin on immunohistochemistry (IHC). The resection
margins were free. The final diagnosis of malignant spin-
dle cell tumor – leiomyosarcoma of jejunum was made.
Due to negative margins and no evidence of disease else-
where, no adjuvant therapy was planned and patient was
kept on regular follow up. He was assessed clinically at
three months interval and an USG of abdomen was per-
formed six monthly. Patient remained disease free for 39
months. After that a follow-up USG showed a space-occu-
pying lesion (SOL) in segment VII of liver and a mass
lesion in left upper abdomen. The patient was asympto-
matic and abdominal examination revealed no abnormal-
ity. A computerized tomographic (CT) scan of abdomen
was performed which showed a 2 × 2 cms, brightly
enhancing SOL in segment VII of liver (Figure 1) and a 3
× 4 cms omental mass lesion abutting the bowel loop in
left upper abdomen (Figure 2). Upper GI endoscopy and
colonoscopy did not reveal any abnormality. A provi-
sional diagnosis of recurrent leiomyosarcoma was made.
Patient was planned for resection of the mass and RFA of
liver lesion.
Patient was explored and two separate well encapsulated,
fleshy mass lesions were found in infracolic omentum,
measuring 6 × 7 × 3.5 and 2 × 1 × 1 cms. The liver lesion
was not palpable and there was no evidence of disease at
primary site or anywhere else in peritoneal cavity. An
infracolic omentectomy along with tumor nodules was
performed.
The histopathological features were suggestive of a highly
cellular tumor composed of spindle shaped cells arranged
in interlacing fascicles. On immunohistochemistry, multi-
ple sections were negative for CD-34, CD-117, S-100 and
desmin but focally positive for actin as in the initial
tumor. So a diagnosis of recurrent leiomyosarcoma was
made. The patient was taken up for an USG guided RFA of
liver metastasis 3 weeks after surgery. The RFA was per-
formed by Cool Tip™ RF machine [Radionics, USA] using
single tip probe. The procedure was conducted for 12
minutes at temperature of 65°C and the lesion was
ablated with 1 cm margin. Follow-up CT scan done 3 days
later showed complete ablation of metastatic lesion (Fig-
ure 3). The patient was kept on regular follow-up and nine
months after RFA he was asymptomatic and an abdomi-
nal CT scan showed no evidence of recurrence.
Discussion
The small intestine accounts for 75% of total length of GI
tract and more than 90% of mucosal surface. However, it
is the site of only 6–25% of GI neoplasms and only 2% of
GI malignancies [2,6]. Leiomyosarcoma is the fourth
most common malignant tumor of small bowel and it'sWorld Journal of Surgical Oncology 2005, 3:3 http://www.wjso.com/content/3/1/3
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incidence is 1.2 cases/million/year [7,8].The most fre-
quent site of leiomyosarcoma is jejunum, followed by
ileum and duodenum [6,8]. The peak incidence is in 6th
decade and there is a slight male preponderance [6].
Most of these tumors are slow growing and associated
with a long period of symptoms [8]. The most common
presentation is GI bleeding and anemia [6]. Abdominal
pain and palpable mass is present in 5–50% of patients
[6]. Other symptoms include nausea, vomiting and weak-
ness [7]. Nonetheless, there is no specific sign or symptom
that defines presentation of smooth muscle tumors [7].
Our patient presented with features of GI bleed, anemia
and recurrent subacute intestinal obstruction.
Intestinal obstruction is seen in less than 5% patients with
smooth muscle tumor and is usually caused by tumor
infiltration or malignant adhesions [6,7]. In the present
case, the cause of obstruction was intussusception. In
adult patients, small bowel intussusception is caused
mostly by small benign intraluminal ileal tumors like
lipoma and leiomyoma [6,8]. However, in this patient
intraluminal component of dumb bell jejunal leiomyosa-
rcoma was causing intussusception. Intussusception is a
rare phenomenon in patients with leiomyosarcoma and
tumors of ileal region presents with intussusception more
often than jejunal location [6]. Review of English litera-
ture revealed only one case of jejunal intussusception
caused by leiomyosarcoma [9]. The commonly
CT scan image showing the hepatic metastasis in segment VII Figure 1
CT scan image showing the hepatic metastasis in segment VII.World Journal of Surgical Oncology 2005, 3:3 http://www.wjso.com/content/3/1/3
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recommended investigations in cases of suspected small
bowel tumor are endoscopy, CT scan and contrast studies
and most often the final diagnosis is confirmed after
laparotomy and histopathology [6] as happened in the
present case. The preoperative tissue diagnosis is not rou-
tinely recommended except in suspected cases of lym-
phoma, germ cell tumor and unresectable metastatic
disease because of theoretical risk of peritoneal seeding
and tumor rupture along with difficulty in obtaining
definitive diagnosis [10,11].
Majority of leiomyosarcoma grow extraluminally but
infrequently tumor can grow both extra and intralumi-
nally. Blanchard et al in their extensive review of small
bowel leiomyosarcoma found that 68% of jejunal tumors
grow extraluminally and only 14.4% in dumb bell fash-
ion [6]. Tumor size varied from 1–20 cm and in >3/4th of
patients tumor is >5 cm. In the present case, the tumor
was 7.5 cms and had grown in a dumb bell fashion.
The surgical resection is the mainstay of treatment in these
tumors [6,7]. The surgery usually involves the en bloc
resection of tumor with wide margins along with adjacent
mesentery [6]. The lymphatic spread of leiomyosarcoma
to regional lymph nodes occurs in 5%–13% of patients
and role of lymph node dissection is controversial. How-
ever, routine lymph nodal dissection in the absence of
nodal disease is not recommended [7].
Unfortunately, leiomyosarcomas are notoriously radiore-
sistant and attempts at using adjunctive radiotherapy and
chemotherapy have failed [12,13]. There is no role of
CT scan image showing the omental mass adjacent to bowel loop (circle around the omental mass) Figure 2
CT scan image showing the omental mass adjacent to bowel loop (circle around the omental mass).World Journal of Surgical Oncology 2005, 3:3 http://www.wjso.com/content/3/1/3
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adjuvant therapy and patients with complete resection are
kept on close follow-up [6,7,13]. Periodic USG or CT scan
is recommended, as biologically these tumors are hetero-
geneous and aggressive in nature [10]. Similar guidelines
were followed in this patient.
The differentiation between benign and malignant
smooth muscle tumors is difficult and metastasis is the
only conclusive evidence of malignancy. Similar to other
sarcomas, the most common route of metastasis is hema-
togenous and common sites are liver and lungs. But
unlike other sarcomas peritoneal seeding is more com-
monly seen [6]. Blanchard et al reported 41.3% incidence
of metastasis in jejunal leiomyosarcoma and liver was the
most common site followed by peritoneum and mesen-
tery [6]. They also found recurrent tumors in 40.9% of
patients in conjunction with metastatic disease. A similar
picture was present in our patient.
Ranchod and Kempson [14] reported that number of
mitosis is the single most criterion for predicting the met-
astatic potential and tumors with ≥5 mitosis per 10 high
power fields (HPFs) behaved more aggressively. A tumor
that shows >2 mitosis/HPF is usually considered malig-
nant [6]. The size of tumor is also considered in risk strat-
ification for metastasis and tumors <5 cms are
significantly less likely to metastasize [6]. With this crite-
rion, our patient falls into high-risk group for relapse.
Post radiofrequency ablation CT scan image showing complete resolution of hepatic metastasis Figure 3
Post radiofrequency ablation CT scan image showing complete resolution of hepatic metastasis.World Journal of Surgical Oncology 2005, 3:3 http://www.wjso.com/content/3/1/3
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Overall reported survival rate for GI leiomyosarcoma is
10–48% [6]. But in an analysis of six series, Licht et al [15]
reported only 5–20%, 5-year survival for high-grade
tumors (tumors with >10 mitosis per 10 HPFs).
O'Riordan et al [8] reported 5-year survival rate of 27% for
tumors >5 cms. In a series of 21 patients with high grade
leiomyosarcomas, Chou et al found that 17 of their cases
had liver metastasis or local recurrence [16].
Conlon et al [17] reported 44% recurrence after complete
resection, and mean time to recurrence was 9 months
(median 7, ranging from <1 to 37 months). Despite the
high-risk, our patient had relapse after 40 months of pri-
mary surgery and the relapse sites were omentum and
liver, without having any evidence of disease at primary
site.
A few patients benefit from surgical intervention for
removal of metastasis in small bowel leiomyosarcoma
[7]. Karakousis et al, [18] reported prolongation of sur-
vival after metastasectomy in intestinal leiomyosarcoma
and 3 year survival of 28%. Kohno et al [19] described 10-
years survival after multiple surgeries in a patient of intes-
tinal leiomyosarcoma. Considering the good general con-
dition of our patient, long disease free interval and limited
bulk of disease, we planned for resection of omental
recurrence and treat the liver lesion with RFA.
Most of the experience of liver metastasis management is
in colorectal malignancy and there is limited experience
of liver resection in noncolorectal cancers [20]. There are
different types of therapy for the management of liver
metastasis – surgical resection, regional treatment modal-
ities, systemic therapy and local or in situ ablation [21].
Although, the gold standard is surgical resection however
only 15–25% of patients with liver metastasis are suitable
for hepatic resections [20,21]. In soft tissue sarcoma; in a
selected group of patients, metastatectomy is recom-
mended [22].
Due to high morbidity and mortality and limited survival
after liver resection, recently, in situ ablation of liver
metastasis with radiofrequency ablation is gaining popu-
larity [5,20,21]. RFA is ideally suitable for single lesion <5
cm in size and complication rate of RFA is usually very low
[23]. The effectiveness of RFA has been demonstrated in
few retrospective studies but long-term results are awaited
[24].
Considering the very high-risk of relapse in leiomyosar-
coma and a deep-seated liver metastasis requiring major
hepatic resection, we planned for the RFA of liver lesion.
Until now, there are only a few reports of use of RFA in
treatment of liver metastasis in leiomyosarcoma [25,26].
Tepetes et al [25] reported 5-year survival in a case of
hepatic metastasis from leiomyosarcoma with combina-
tion of liver resection, RFA and systemic chemotherapy.
Karakousis et al [18] reported 3 and 5 years survival as
28% and 4% respectively after complete resection of
metastasis in intestinal leiomyosarcoma. However, sur-
vival was limited to 6 months for high-grade leiomyosar-
coma. Despite a high-risk tumor and having local relapse
with liver metastasis, our patient is still disease free after 9
months of second surgery and 4 years after first surgery.
Conclusion
Jejunal leiomyosarcoma is a rare variety of malignant
small bowel tumor with diverse presentation, heterogene-
ous behavior and a high propensity for relapse. Clinical
presentation with intussusception is unusual. We suggest
that an aggressive management approach using a combi-
nation of surgery and a new technique like RFA can be
attempted in patients with limited metastatic spread to
liver to prolong the long term survival in a subset of
patients.
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